Results 21 to 30 of about 46,038 (143)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

Pharmaceuticals, 2013
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex, Di Simpson, Anthony G. Catto-Smith, Oliver Gouldthorpe   +3 more
doaj   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Arthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich   +3 more
doaj   +1 more source

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

Journal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor, Ali Altaqi, Abdulnasser Abdullah, Amer Khudhairy   +3 more
doaj   +1 more source

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC Gastroenterology, 2022
Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in ...
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya   +15 more
doaj   +1 more source

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis

Frontiers in Pediatrics, 2021
Background: Data on serum infliximab concentrations during induction in pediatric ulcerative colitis are limited. The study aim is to evaluate the relationship between serum infliximab concentrations during induction and short-term clinical remission in ...
Jennifer C. C. deBruyn, Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh   +10 more
doaj   +1 more source

Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System

Children
Background/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies.
Ross M. Maltz, Shehzad A. Saeed, Jeremy Adler   +2 more
doaj   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Pharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. [PDF]

PLoS ONE, 2017
Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a ...
Franco Scaldaferri, Daria D'Ambrosio, Grainne Holleran, Andrea Poscia, Valentina Petito, Loris Lopetuso, Cristina Graziani, Lucrezia Laterza, Maria Teresa Pistone, Silvia Pecere, Diego Currò, Eleonora Gaetani, Alessandro Armuzzi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini   +15 more
doaj   +1 more source

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial

Scientific Reports, 2018
We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG.
Masaaki Mori, Takuma Hara, Masako Kikuchi, Hiroyuki Shimizu, Tomoyuki Miyamoto, Satoru Iwashima, Tatsuya Oonishi, Kunio Hashimoto, Norimoto Kobayashi, Kenji Waki, Yasuo Suzuki, Yoshikazu Otsubo, Hiroshi Yamada, Chikao Ishikawa, Taichi Kato, Shigeto Fuse   +15 more
doaj   +1 more source

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy

Case Reports in Gastroenterology, 2009
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease (CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully evaluated.
Manzurul Chowdhury, Norihiko Kudara, Toshimi Chiba, Masaki Endo, Risaburo Akasaka, Kazumitsu Tomita, Saori Fujiwara, Tomomi Mizutani, Tamotsu Sugai, Yasuhiro Takikawa, Kazuyuki Suzuki   +10 more
doaj   +1 more source